MX2023003376A - Compuesto para la prevencion o el tratamiento de afecciones mediadas por autoanticuerpos. - Google Patents
Compuesto para la prevencion o el tratamiento de afecciones mediadas por autoanticuerpos.Info
- Publication number
- MX2023003376A MX2023003376A MX2023003376A MX2023003376A MX2023003376A MX 2023003376 A MX2023003376 A MX 2023003376A MX 2023003376 A MX2023003376 A MX 2023003376A MX 2023003376 A MX2023003376 A MX 2023003376A MX 2023003376 A MX2023003376 A MX 2023003376A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- amino acid
- amino
- autoantibody
- peptides
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 abstract 2
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000031976 Channelopathies Diseases 0.000 abstract 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002567 autonomic effect Effects 0.000 abstract 1
- 229920001222 biopolymer Polymers 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002265 sensory receptor cell Anatomy 0.000 abstract 1
- 230000009919 sequestration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Electroluminescent Light Sources (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un compuesto para el secuestro de anticuerpos no deseables asociados con una afección mediada por autoanticuerpos, tal como encefalomielitis miálgica/síndrome de fatiga crónica (ME/CFS), síndrome de taquicardia ortostática postural (POTS), gangliopatía autonómica autoinmune (AAG), miocardiopatía dilatada idiopática (IDC) y cardiopatía chagásica crónica (cChHD) u otros trastornos neurológicos, neuromusculares y neuropsiquiátricos, en particular canalopatías autoinmunes. El compuesto comprende un andamio de biopolímero y al menos dos péptidos con una longitud de secuencia de 6 a 13 aminoácidos en donde cada uno de los péptidos independientemente comprende un fragmento de 6 aminoácidos de una secuencia de aminoácidos de un neuroreceptor humano, opcionalmente en donde como máximo tres, preferiblemente como máximo dos, lo más preferiblemente máximo un aminoácido está sustituido independientemente por cualquier otro aminoácido. También se proporcionan composiciones farmacéuticas que comprenden el compuesto, así como métodos para mejorar o tratar las afecciones mencionadas anteriormente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20197934 | 2020-09-23 | ||
PCT/EP2021/076176 WO2022063882A1 (en) | 2020-09-23 | 2021-09-23 | Compound for the prevention or treatment of autoantibody-mediated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003376A true MX2023003376A (es) | 2023-03-31 |
Family
ID=72644088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003376A MX2023003376A (es) | 2020-09-23 | 2021-09-23 | Compuesto para la prevencion o el tratamiento de afecciones mediadas por autoanticuerpos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230355784A1 (es) |
EP (1) | EP4217402A1 (es) |
JP (1) | JP2023542389A (es) |
KR (1) | KR20230074641A (es) |
CN (1) | CN116635081A (es) |
AU (1) | AU2021347581A1 (es) |
BR (1) | BR112023005257A2 (es) |
CA (1) | CA3192740A1 (es) |
IL (1) | IL301332A (es) |
MX (1) | MX2023003376A (es) |
WO (1) | WO2022063882A1 (es) |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US5372933A (en) | 1988-10-03 | 1994-12-13 | The Scripps Research Institute | Polypeptides that mimic receptor-induced binding sites, and methods of using same |
US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
US6897287B1 (en) | 1990-01-31 | 2005-05-24 | Oklahoma Medical Research Foundation | Ro/SSA peptide reagents for diagnosis of autoantibodies |
US7888458B1 (en) | 1993-11-30 | 2011-02-15 | John B. Harley | Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
JP2002531531A (ja) | 1998-12-09 | 2002-09-24 | ラ ホヤ ファーマシューティカル カンパニー | 循環している抗体を減少させるための方法および処方物 |
DE60140069D1 (de) | 2000-10-16 | 2009-11-12 | Cytoguide Aps | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür |
WO2004067549A2 (de) | 2003-01-31 | 2004-08-12 | Max-Delbrück-Centrum für Molekulare Medizin | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung |
WO2004089422A2 (en) | 2003-03-30 | 2004-10-21 | La Jolla Pharmaceutical Co. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
CA2697108C (en) * | 2007-08-24 | 2018-05-22 | Julius-Maximilians-Universitaet Wuerzburg | Mutant double cyclized receptor peptides inhibiting .beta.1-adrenoceptor antibodies |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
BR112012026003B1 (pt) | 2010-04-13 | 2022-03-15 | Medimmune, Llc | Estrutura multimérica recombinante específica trail r2, seu uso, bem como composição |
EP2402016A1 (en) | 2010-06-29 | 2012-01-04 | Charité - Universitätsmedizin Berlin | Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor |
EP2497828A1 (en) * | 2011-03-07 | 2012-09-12 | Charité - Universitätsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
EP3059244B1 (en) | 2013-10-15 | 2020-08-26 | The University of Tokyo | C-met protein agonist |
PL3116887T3 (pl) | 2014-03-13 | 2021-09-06 | Universität Basel | Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną |
WO2015181393A1 (en) | 2014-05-30 | 2015-12-03 | Per-Johan Jakobsson | Novel sfti and cyclotide based peptides |
EP2982756A1 (en) | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
US11091591B2 (en) | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
AU2017366674A1 (en) | 2016-12-02 | 2019-06-20 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
US20190374650A1 (en) * | 2017-02-22 | 2019-12-12 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer/biomacromolecule conjugates |
-
2021
- 2021-09-23 JP JP2023518816A patent/JP2023542389A/ja active Pending
- 2021-09-23 KR KR1020237013947A patent/KR20230074641A/ko unknown
- 2021-09-23 CN CN202180075991.8A patent/CN116635081A/zh active Pending
- 2021-09-23 BR BR112023005257A patent/BR112023005257A2/pt unknown
- 2021-09-23 CA CA3192740A patent/CA3192740A1/en active Pending
- 2021-09-23 EP EP21777810.9A patent/EP4217402A1/en active Pending
- 2021-09-23 US US18/246,110 patent/US20230355784A1/en active Pending
- 2021-09-23 AU AU2021347581A patent/AU2021347581A1/en active Pending
- 2021-09-23 MX MX2023003376A patent/MX2023003376A/es unknown
- 2021-09-23 WO PCT/EP2021/076176 patent/WO2022063882A1/en active Application Filing
- 2021-09-23 IL IL301332A patent/IL301332A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN116635081A (zh) | 2023-08-22 |
JP2023542389A (ja) | 2023-10-06 |
KR20230074641A (ko) | 2023-05-30 |
WO2022063882A1 (en) | 2022-03-31 |
CA3192740A1 (en) | 2022-03-31 |
BR112023005257A2 (pt) | 2023-04-25 |
AU2021347581A9 (en) | 2024-06-27 |
AU2021347581A1 (en) | 2023-05-18 |
EP4217402A1 (en) | 2023-08-02 |
IL301332A (en) | 2023-05-01 |
US20230355784A1 (en) | 2023-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Szczudlik et al. | Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society–part two | |
JP7360419B2 (ja) | 安定化抗微生物性ペプチド | |
Dobson | Addressing the global burden of trauma in major surgery | |
Sinoway et al. | A perspective on the muscle reflex: implications for congestive heart failure | |
US20200338165A1 (en) | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure | |
JP2019077723A (ja) | 抗CTLA−4抗体又は抗PD−1抗体との併用におけるIL−2Rβ選択的作動薬 | |
Ihm et al. | Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines?―An Asian Perspective― | |
US9062125B2 (en) | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission | |
Nobile-Orazio | Multifocal motor neuropathy. | |
WO2011133919A4 (en) | Use of tau to monitor immunotherapy | |
AR080564A1 (es) | Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) | |
Trotter et al. | Amyloidosis with plasma cell dyscrasia: an overlooked cause of adult onset sensorimotor neuropathy | |
EA202290024A1 (ru) | Способы лечения болезни фабри у пациентов с почечной недостаточностью | |
MX2023003376A (es) | Compuesto para la prevencion o el tratamiento de afecciones mediadas por autoanticuerpos. | |
Cirillo et al. | Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin | |
JP2020531520A5 (es) | ||
KR20170104535A (ko) | 지속형 epo 제제를 이용한 빈혈 치료 방법 | |
EA201300063A1 (ru) | Способ лечения острого нарушения мозгового и спинального кровообращения ишемического и геморрагического характера | |
JP2024511066A (ja) | 不適応ストレス応答から生じる疾患を治療する改善された方法 | |
Legrady et al. | Observations of changes of blood pressure before and after neurosurgical decompression in hypertensive patients with different types of neurovascular compression of brain stem | |
JP2019530741A5 (es) | ||
EA202092472A1 (ru) | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности | |
Pitarokoili et al. | Journal of Translational Autoimmunity | |
CA3069256A1 (en) | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf | |
MX2023003375A (es) | Compuesto para aumentar la eficacia de la terapia de sustitucion del factor viii. |